http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105412123-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 |
| filingDate | 2015-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105412123-B |
| titleOfInvention | Application of budesonide joint antifungal drug in triazole class and products thereof |
| abstract | The invention discloses application of a kind of budesonide joint antifungal drug in triazole class and products thereof, BUD respectively with FLC, ITR, VRC use in conjunction when, antibacterial activity of the antifungal drug in triazole class to resistance CA can be strengthened, collaboration antifungic action can be produced, and can reversing drug resistance CA to the drug resistance of antifungal drug in triazole class, exploitation and old medicine for new drug are new with providing research direction.To the CA of the common resistance of FLC, ITR, VRC, drug combination can be such that its minimum inhibitory concentration substantially reduces, 32 μ g/mL BUD and 1 μ g/mL FLC are shared, 64 μ g/mL BUD and 0.0313~0.125 μ g/mL ITR are shared and 64 μ g/mL BUD and 0.0313~0.0625 μ g/mL VRC share can kill more than 80% fungi, concentration increases again, and effect is stronger. |
| priorityDate | 2015-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.